Aims: Diagnosis of lymphoma includes besides H&E diagnostics a number of histochemical and immunohistochemical methods because of the variety of different lymphoma subtypes. Compared to other tumor entities, single lymphoma subtypes are characterized by a relative homogeneity. For this reason, lymphomas are good models for matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging and profiling experiments. Since MALDI MS represents a fast and reliable method, the aim of this study is to investigate the ability of MALDI imaging mass spectrometry (IMS) to generate protein profiles that can distinguish clinical samples of FL from DLBCL, thereby replacing (immune-) histochemistry. Methods: MALDI IMS was used to directly analyze proteins from in total 14 fresh-frozen biopsy sections from patients with either FL or DLBCL. H&E stained sections were evaluated by a pathologist and serial sections were prepared for analysis by applying matrix solution with a spraying device, followed by MALDI IMS analysis using an Autoflex Speed in linear mode. MS images were compared and a subset of the statistically significant discriminator proteins in the regions of interest were then selected and evaluated on the basis of P values from the Wilcoxon/Kruskal-Wallis test. Results: Our preliminary analysis has shown promising results with the detection of twelve protein signatures that could differentiate between follicular lymphoma and DLBCL (p>0,01, 1,7-fold change). Among the detected peaks four m/z signals were considered putative consistent with annotated values for histones. Conclusion: This pilot study was done to assess the efficacy of MALDI MS to discriminate between follicular lymphoma and DLBCL tissue samples. A more detailed and rigorous study involving a larger sample set is currently being developed, in order to build a model to molecularly classify DLBCL and lymphoma subtypes. In addition, simultaneous investigation of FFPE-biopsies and peptide profiling is necessary in order build a model and apply this technique for a more individualized therapeutic approach in histopathological practice.
Imaging mass spectrometry analysis to distinguish follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) Imaging Massenspektrometrie zur Unterscheidung von Follikulärem Lymphom (FL) und Diff usem großzelligen B-Zell Lymphom (DLBCL)
Casadonte R;
2013-01-01
Abstract
Aims: Diagnosis of lymphoma includes besides H&E diagnostics a number of histochemical and immunohistochemical methods because of the variety of different lymphoma subtypes. Compared to other tumor entities, single lymphoma subtypes are characterized by a relative homogeneity. For this reason, lymphomas are good models for matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging and profiling experiments. Since MALDI MS represents a fast and reliable method, the aim of this study is to investigate the ability of MALDI imaging mass spectrometry (IMS) to generate protein profiles that can distinguish clinical samples of FL from DLBCL, thereby replacing (immune-) histochemistry. Methods: MALDI IMS was used to directly analyze proteins from in total 14 fresh-frozen biopsy sections from patients with either FL or DLBCL. H&E stained sections were evaluated by a pathologist and serial sections were prepared for analysis by applying matrix solution with a spraying device, followed by MALDI IMS analysis using an Autoflex Speed in linear mode. MS images were compared and a subset of the statistically significant discriminator proteins in the regions of interest were then selected and evaluated on the basis of P values from the Wilcoxon/Kruskal-Wallis test. Results: Our preliminary analysis has shown promising results with the detection of twelve protein signatures that could differentiate between follicular lymphoma and DLBCL (p>0,01, 1,7-fold change). Among the detected peaks four m/z signals were considered putative consistent with annotated values for histones. Conclusion: This pilot study was done to assess the efficacy of MALDI MS to discriminate between follicular lymphoma and DLBCL tissue samples. A more detailed and rigorous study involving a larger sample set is currently being developed, in order to build a model to molecularly classify DLBCL and lymphoma subtypes. In addition, simultaneous investigation of FFPE-biopsies and peptide profiling is necessary in order build a model and apply this technique for a more individualized therapeutic approach in histopathological practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
